UNCY
NASDAQ HealthcareUnicycive Therapeutics, Inc. - Common Stock
Biotechnology
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
�� 市场数据
| 价格 | $7.23 |
|---|---|
| 成交量 | 901,145 |
| 市值 | 193.04M |
| RSI（14日） | 37.7 |
| 200日均线 | $5.97 |
| 50日均线 | $7.30 |
| 52周最高 | $11.00 |
| 52周最低 | $3.71 |
| Forward P/E | 1.20 |
| Price / Book | 4.84 |
🎯 投资策略评分
UNCY 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (50/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (4/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 UNCY in your text
粘贴任何文章、记录或帖子 — 工具将提取 UNCY 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.